GRI Bio reiterates fiscal 2025 results in new 8-K
GRI Bio, Inc. filed a current report describing that it issued a press release on February 4, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
GRI Bio, Inc. filed a current report describing that it issued a press release on February 4, 2026. The release reiterates the company’s financial results for fiscal year 2025 and summarizes key recent business highlights.
The press release is furnished as Exhibit 99.1 and is not incorporated by reference into other SEC filings or deemed filed for liability purposes.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did GRI Bio, Inc. (GRI) disclose in its latest 8-K filing?
GRI Bio, Inc. disclosed that it issued a press release reiterating its financial results for fiscal year 2025 and summarizing recent highlights. The release is provided as Exhibit 99.1 and is furnished, not filed, for securities law purposes.
Which period’s results does GRI Bio’s February 2026 press release cover?
The press release furnished by GRI Bio, Inc. reiterates the company’s financial results for its fiscal year 2025. It also summarizes key recent highlights, giving investors a consolidated update on performance and recent corporate developments in one communication.
How is Exhibit 99.1 treated in GRI Bio’s 8-K filing?
Exhibit 99.1, GRI Bio, Inc.’s press release dated February 4, 2026, is furnished rather than filed. This means it is not subject to Section 18 liability and is not automatically incorporated into other SEC filings by reference.
Which SEC item does GRI Bio use to report its 2025 results press release?
GRI Bio, Inc. uses Item 2.02, Results of Operations and Financial Condition, to report that it issued a press release reiterating fiscal year 2025 financial results and recent highlights. This item is commonly used for earnings-related disclosures.
Who signed the February 4, 2026 8-K for GRI Bio, Inc.?
The 8-K filed by GRI Bio, Inc. dated February 4, 2026 was signed on behalf of the company by Leanne Kelly, its Chief Financial Officer. This signature indicates authorized officer approval of the furnished information and exhibits.
What other exhibit is included in GRI Bio’s February 2026 8-K besides the press release?
In addition to the press release in Exhibit 99.1, GRI Bio, Inc. includes Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document. This supports structured data reporting for the cover page information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| of incorporation) | ||||||||||||||
(Address of principal executive offices and zip code)
(619 ) 400-1170
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The Nasdaq Capital Market | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging Growth Company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 4, 2026, GRI Bio, Inc. (the “Company”) issued a press release reiterating its financial results for the fiscal year 2025 and summarizing key recent highlights. A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying Exhibit 99.1 shall not be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release issued by GRI Bio, Inc., dated February 4, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 4, 2026 | GRI Bio, Inc. | |||||||
| By: /s/ Leanne Kelly | ||||||||
| Leanne Kelly | ||||||||
| Chief Financial Officer | ||||||||